Evidence map›Paper›PMID 40875626›Full record

ArticlePloS one2025

Machine learning-based identification of diagnostic and prognostic mitotic cell cycle genes in hepatocellular carcinoma.

Ceren Sucularli

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Ceren SucularliDepartment of Bioinformatics, Institute of Health Sciences, Hacettepe University, Ankara, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mitotic cell cycle (MCC) is a critical process in cell growth and division, and dysregulation of MCC genes may contribute to tumorigenesis. In this study, to identify diagnostic and prognostic value of MCC genes, differentially expressed MCC genes between HCC and normal tissues were identified and subjected to machine learning methods. SVM-RFE and RF-RFE were employed to select the most informative diagnostic genes. The SVM-RFE model demonstrated high performance in TCGA (AUC = 1.0), and generalizability across GSE77509 (AUC = 0.95) and GSE144269 (AUC = 0.879), outperforming RF-RFE. Permutation testing confirmed that these AUCs were outside the null distribution for all datasets. Nine genes, CDKN3, TRIP13, RACGAP1, FBXO43, EZH2, SPDL1, E2F1, TUBE1 and CDC6, were common in SVM-RFE and RF-RFE and showed robust individual diagnostic performance across datasets (AUCs > 0.81). Univariate Cox regression followed by LASSO Cox regression was used for identification of prognostic gene signature consisted of eight MCC genes, BCAT1, DPF1, CDKN2B, CDKN2C, TUBA3C, IGF1, CDC14B and SMARCA2, that predicted overall survival of HCC patients. The risk score was shown to be an independent prognostic factor for HCC and its combination with AJCC stage improved prognostic value. Kaplan-Meier analysis showed that high-risk score was associated to poorer survival across clinical subgroups; stage, grade, age, and gender. Additionally, risk score was significantly higher in patients with advanced-stage and high-grade tumors. In conclusion, diagnostic biomarker candidates classifying HCC patients and healthy controls, and a novel prognostic gene signature predicting overall survival of HCC patients were identified by using machine learning approaches.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsMachine LearningMitosisBiomarkers, TumorFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleMiddle AgedPrognosisBiomarkers, Tumor

Identifiers

PMID40875626
PMCPMC12393733

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.